213 related articles for article (PubMed ID: 19551314)
21. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass.
Chandler WL; Velan T
Thromb Res; 2003; 112(3):185-92. PubMed ID: 14967416
[TBL] [Abstract][Full Text] [Related]
22. [Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in children with ulcerative colitis].
Grabarczyk E; Szaflarska-Popławska A; Góralczyk K; Rość D
Pol Merkur Lekarski; 2006 Mar; 20(117):326-8. PubMed ID: 16780267
[TBL] [Abstract][Full Text] [Related]
23. [Tissue plasminogen activator and plasminogen activator inhibitor in aqueous humor].
Giedrojć J; Stankiewicz A; Walkowiak M; Galar M; Bielawiec M
Klin Oczna; 1996; 98(4):283-5. PubMed ID: 9463119
[TBL] [Abstract][Full Text] [Related]
24. Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.
Speidl WS; Nikfardjam M; Niessner A; Zeiner A; Jordanova N; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
Thromb Res; 2007; 119(3):331-6. PubMed ID: 16616324
[TBL] [Abstract][Full Text] [Related]
25. [The fibrinolytic system in patients with dilated myocardiopathy].
Fernández P; Marín F; Marco P; Roldán V; García MC; Martínez JG; Sogorb F; Calatayud R
Sangre (Barc); 1996 Oct; 41(5):351-5. PubMed ID: 9026920
[TBL] [Abstract][Full Text] [Related]
26. Human gender differences in fibrinolytic responses to exercise training and their determinants.
Kulaputana O; Macko RF; Ghiu I; Phares DA; Goldberg AP; Hagberg JM
Exp Physiol; 2005 Nov; 90(6):881-7. PubMed ID: 16118237
[TBL] [Abstract][Full Text] [Related]
27. Association between platelet activation and fibrinolysis in acute stroke patients.
Wang J; Li J; Liu Q
Neurosci Lett; 2005 Aug; 384(3):305-9. PubMed ID: 15916851
[TBL] [Abstract][Full Text] [Related]
28. Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
Stehling F; Weber R; Ozcelik A; Bröcker M; Volbracht L; Diener HC; Busch E
Neurosci Lett; 2008 Aug; 441(1):39-43. PubMed ID: 18597942
[TBL] [Abstract][Full Text] [Related]
29. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH
Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655
[TBL] [Abstract][Full Text] [Related]
30. [The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue].
Ziółkowska E; Pietrusińska E; Łozyńska-Podhrebelna D
Pol Merkur Lekarski; 2008 Dec; 25(150):489-94. PubMed ID: 19205379
[TBL] [Abstract][Full Text] [Related]
31. Altered endothelial function following the Fontan procedure.
Binotto MA; Maeda NY; Lopes AA
Cardiol Young; 2008 Feb; 18(1):70-4. PubMed ID: 18093358
[TBL] [Abstract][Full Text] [Related]
32. Fibrinolytic system in normotensive subjects and hypertensive patients.
Armas-Hernández MJ; Hernández-Hernández R; Armas-Padilla MC; Sosa-Canache B; Cammarata R; Pacheco B; Guerrero-Pajuelo J; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):177-82. PubMed ID: 17414587
[TBL] [Abstract][Full Text] [Related]
33. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
34. Tissue-type plasminogen activator in patients with intracranial meningiomas.
Tsuda H; Oka K; Noutsuka Y; Sueishi K
Thromb Haemost; 1988 Dec; 60(3):508-13. PubMed ID: 3149049
[TBL] [Abstract][Full Text] [Related]
35. Tissue plasminogen activator (t-PA) and placental plasminogen activator inhibitor (PAI-2) in gingival crevicular fluid from patients with Papillon-Lefèvre syndrome.
Ullbro C; Kinnby B; Lindberg P; Matsson L
J Clin Periodontol; 2004 Sep; 31(9):708-12. PubMed ID: 15312091
[TBL] [Abstract][Full Text] [Related]
36. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
[TBL] [Abstract][Full Text] [Related]
37. Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus.
Kwieciński J; Kłak M; Trysberg E; Blennow K; Tarkowski A; Jin T
Arthritis Rheum; 2009 Jul; 60(7):2094-101. PubMed ID: 19565516
[TBL] [Abstract][Full Text] [Related]
38. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
[TBL] [Abstract][Full Text] [Related]
39. [Alterations of fibrinolysis in stroke].
Hernández Nuñez A; Romero Barbero JL; Cáceres Sansaloni A; Pérez de Oteyza C
An Med Interna; 1996 Mar; 13(3):107-10. PubMed ID: 8679836
[TBL] [Abstract][Full Text] [Related]
40. Effects of cardiac rehabilitation on fibrinolysis in patients with coronary artery disease.
Anomasiri W; Thongthawee B
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S242-8. PubMed ID: 16623036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]